BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37540187)

  • 1. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
    Li B; Li Y; Zhou H; Xu Y; Cao Y; Cheng C; Peng J; Li H; Zhang L; Su K; Xu Z; Hu Y; Lu J; Lu Y; Qian L; Wang Y; Zhang Y; Liu Q; Xie Y; Guo S; Mehal WZ; Yu D
    Hepatology; 2024 Feb; 79(2):289-306. PubMed ID: 37540187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy.
    Xing X; Hu E; Ouyang J; Zhong X; Wang F; Liu K; Cai L; Zhou Y; Wang Y; Chen G; Li Z; Wu L; Liu X
    Cell Rep Med; 2023 Dec; 4(12):101315. PubMed ID: 38091986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Zhao S; Zhou M; Wang P; Yang J; Zhang D; Yin F; Song P
    Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
    [No Abstract]   [Full Text] [Related]  

  • 5. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
    Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
    Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
    An J; Han S; Kim HI; Shim JH
    Hepatol Commun; 2022 Oct; 6(10):2886-2900. PubMed ID: 35785525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.
    Wu R; Gao Y; Zhao X; Guo S; Zhou H; Zhang Y; Hou Y; Mei L; Zhi H; Wang P; Li X; Ning S; Zhang Y
    Comput Biol Med; 2023 Dec; 167():107593. PubMed ID: 37883849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    He K; Yang Z; Liu X; Yang Y; Song W; Wang S; Chen Y
    Curr Oncol; 2022 Dec; 30(1):476-491. PubMed ID: 36661687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes.
    Xie Y; Tian H; Xiang B; Zhang Y; Liu J; Cai Z; Xiang H
    Medicine (Baltimore); 2021 Aug; 100(33):e26958. PubMed ID: 34414963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
    BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
    Xiong X; Song Q; Jing M; Yan W
    Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
    Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
    BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
    He Q; Yang J; Jin Y
    Front Immunol; 2022; 13():869993. PubMed ID: 35493518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
    Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
    Cao Y; Ouyang T; Xiong F; Kan X; Chen L; Liang B; Zheng C
    Hepatol Int; 2021 Oct; 15(5):1268-1277. PubMed ID: 34415515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.